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ABSTRACT 
Transcriptional regulation can occur through the modification and remodeling of 
chromatin, which consists of DNA, histones, and non-histone proteins. One such 
mechanism that controls gene expression is the chemical modification of histones. The 
Polycomb repressive complex 2 (PRC2) is a histone-modifying complex that catalyzes 
the trimethylation of lysine 27 on histone H3 (H3K27me3), a modification that is 
associated with transcriptional repression. PRC2 consists of the core proteins EZH2, 
EED, and SUZ12, along with other co-factors. Essential insights into PRC2 function 
have occurred through the study of its involvement in X-chromosome inactivation. X-
inactivation is an epigenetic phenomenon by which female mammals achieve dosage 
compensation by silencing genes on one of two X chromosomes. PRC2 core proteins 
as well as H3K27me3 are physically enriched on the inactive X-chromosome. Our lab 
has found, however, that in mouse extra-embryonic endoderm (XEN) cells, H3K27me3 
accumulates on the inactive-X independently of EZH2 enrichment. I tested whether 
H3K27me3 would still be enriched on the inactive-X of XEN cells devoid of EZH2, and I 
discovered that H3K27me3 enrichment on the inactive-X still occurs in Ezh2-/- XEN 
cells. I next tested whether EZH1, a homolog of EZH2, is responsible for this residual 
H3K27me3, and I found that while enrichment of H3K27me3 on the inactive-X was 
ablated in Ezh2-/-;Ezh1-/- XEN cells, global levels of H3K27me3 were unaffected when 
compared to Ezh2-/- XEN cells by Western blotting. Additionally, I observed a similar 
outcome in Eed-/- XEN cells. These data suggest that although PRC2 is required for 
enrichment of H3K27me3 on the inactive-X, a PRC2-independent histone 
methyltransferase is capable of catalyzing H3K27me3 in XEN cells.  
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INTRODUCTION 
Chromatin is composed of more than just the condensed DNA sequence that 
contains the genetic information necessary for life. In addition to DNA, chromatin 
consists of nucleosomes, which are octamers composed of 4 types of core histones 
around which DNA is wrapped, as well as non-histone proteins, which include 
chromatin-modifying enzymes. Each of the core histones, H2A, H2B, H3, and H4, 
contains an N-terminal unstructured domain, or “tail,” which projects outside of the 
structure of the nucleosome and is subject to post-translational modifications. Histone 
tails can be methylated, acetylated, phosphorylated, or subject to addition of other 
chemical groups by histone-modifying enzymes.  
Modifications or combinations of modifications on specific histone residues are 
often associated with distinct transcriptional states of the surrounding genes, including 
active and repressed transcriptional states. It is typically thought that histone 
modifications function either by changing the level of compaction of chromatin or by 
recruiting downstream non-histone proteins that may then impact transcription 
(Shogren-Knaak et al., 2006). For these reasons, as well as the fact that histone 
modifications persist from one cell cycle division to the next, histone modifications have 
been proposed to be carriers of epigenetic information (Kouzarides 2007).  
Epigenetics is the study of stable, heritable changes in transcription that occur 
independently of alterations in the DNA sequence, and epigenetic regulation is now 
recognized as playing a key role both during development and in disease. Although it 
has yet to be fully determined whether histone modifications are capable of 
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autonomously transmitting the epigenetic memory, it is widely believed that they are 
involved in epigenetic processes (Kouzarides 2007).  
The Polycomb repressive complex 2 (PRC2) is a complex of proteins thought to 
be involved in epigenetically silencing genes. PRC2 catalyzes the trimethylation of 
lysine 27 on histone H3 (H3K27me3). This histone mark is thought to help recruit 
downstream factors that contribute to a silenced transcriptional state (Cao et al., 2002, 
Margueron et al., 2011). It was first suspected that PRC2 could play a role in epigenetic 
regulatory pathways when in Drosophila, embryos devoid of Esc (known as EED in 
mammals), a core member of PRC2, displayed a paradoxical phenotypic outcome. 
Based on the study of these temperature-sensitive esc-/- embryos, in which loss of Esc 
could be observed at various time points, researchers found that Esc is only required for 
developmental fate determination during a discrete window of time during early 
embryogenesis. Interestingly, the defect exhibited in these mutant embryos was at a 
much later stage of embryogenesis than the window of time in which Esc was missing 
during early embryogenesis. Loss of Esc at the later periods of development did not 
result in a defect, despite the fact that Esc is expressed constitutively throughout 
development (Struhl and Brower 1982). These results suggest that Esc acts to establish 
a transcriptional state of homeotic genes allowing for proper developmental fate 
determination, which can be maintained regardless of the presence or absence of Esc 
after that point, suggesting a memory effect. Additionally, PRC2 as a whole further fits 
the profile of an epigenetic regulator because it is allosterically activated by binding to 
the mark it catalyzes (via the EED subunit), providing an intrinsic mechanism for 
propagation and maintenance of H3K27me3 at target sites (Margueron et al., 2009). 
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The core 
members of mammalian 
PRC2 are EZH2, 
SUZ12, and EED, which 
correspond to E(z), 
Suz12, and Esc in 
Drosophila, respectively 
(Figure 1). EZH2 is the 
catalytic subunit that 
methylates histone H3 
through its SET domain (Muller et al., 2002). In Drosophila, E(z), the H3K27me3 
methyltransferase, is a single protein, but in mammals, it exists in the form of two 
homologs: EZH2 and EZH1 (Laible et al., 1997). Although the methyltransferase activity 
of EZH2 is better characterized, EZH1 also contains a SET domain, and there has been 
speculation as to whether it can form an alternative PRC2 complex and catalyze 
H3K27me3 (Shen et al., 2008, Margueron et al., 2008).  
Despite not possessing intrinsic methyltransferase activity, EED, a WD40-repeat 
protein, is arguably the most central component of PRC2. E(z) and EZH2, on their own, 
have been shown to be catalytically deficient, requiring interaction with both Esc/EED 
and Suz12 for robust methylation activity (Kuzmichev et al., 2002, Simon and Kingston 
2009). As demonstrated in an in vitro pull-down assay, EED coordinates binding of 
EZH2 to the other PRC2 components (including SUZ12), since EZH2 does not directly 
interact with any of the other core proteins. At a minimum, interaction with EED and 
Figure 1: Diagram depicting PRC2 catalytic activity and its 
core members EZH2, SUZ12, and EED. EZH2 catalyzes the 
trimethylation of lysine at position 27 on histone H3 
(H3K27me3, red hexagons). 
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SUZ12 is necessary for EZH2 to manifest its full methyltransferase potential (Cao and 
Zhang 2004). Deletion of any of the WD40 repeats after the first 81 amino acids of EED 
results in abolishment of the EED-EZH2 interaction (Cao et al., 2014). Additionally, 
another study in Drosophila has shown that functional Esc is necessary for E(z) catalytic 
activity even in the presence of an interaction between the two proteins, as formation of 
a complex containing a partial mutant Esc protein that still contains the WD40 domains 
for binding E(z), but lacks its N-terminal domain, results in loss of methyltransferase 
activity (Tie et al., 2007). More directly, researchers have shown that in Eed-/- mouse 
embryonic stem (ES) cells, H3K27me3 is depleted in both immunofluorescence (IF) 
assays and Western blotting (Montgomery et al., 2005). Thus, EED is necessary for 
both the formation and catalytic function of the PRC2 complex. As such, Eed-/- embryos 
and cells have commonly been thought of as being effectively “PRC2 null.”  
In addition to its known roles in genome-wide histone methylation, PRC2 is also 
known to be involved in the epigenetic process of X-chromosome inactivation. X-
inactivation, a form of dosage compensation that occurs in mammals, is the 
phenomenon by which XX female mammals globally transcriptionally silence one of two 
X chromosomes in order to equalize X-linked gene expression with XY males. Once the 
inactive-X (Xi) in a given cell has been chosen and silenced during development, with 
few exceptions, it maintains the silent state through mitosis for the remainder of the 
animal’s life (Lyon 1961, Payer and Lee 2008). X-inactivation is stably maintained in the 
somatic cells of all female mammals, thus making it an important model system for the 
study of epigenetic mechanisms and cell memory. The involvement of PRC2 in X-
inactivation was first discovered when it was found that in the extra-embryonic portion of 
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Eed-/- embryonic day (E) 7.5 mouse embryos carrying an XGFP transgene, the inactive-X 
was aberrantly re-activated (Wang et al., 2001).  
PRC2 proteins are thought to be recruited to the inactive-X through the X-linked 
long noncoding RNA Xist (X-inactive specific transcript), which is expressed specifically 
from the inactive-X (Brown et al., 1991). The RNA physically coats the inactive-X, a 
phenomenon that can be visualized through the use of RNA fluorescence in situ 
hybridization (RNA FISH). Transgenic expression of Xist in male ES cells is sufficient to 
recruit PRC2 to the X chromosome, and expression of a mutant version of Xist 
containing a large inversion spanning much of the gene in female blastocyst stage 
mouse embryos is no longer capable of PRC2 recruitment to the Xist-coated X 
chromosome (Plath et al., 2003, Silva et al., 2003). Furthermore, Xist has recently been 
shown to target Jarid2, a PRC2 cofactor, to the inactive-X chromosome (da Rocha et 
al., 2014). Although the mechanism remains unclear, Xist potentially provides a means 
for PRC2 to get to the inactive-X chromosome during X-inactivation.  
PRC2 components such as EZH2 and EED accumulate on the inactive-X along 
with Xist during early mouse embryogenesis, as assessed by immunocytochemistry; 
accordingly, H3K27me3 is also found enriched on the inactive-X in early embryos (Silva 
et al., 2003, Kalantry et al., 2006). Co-localization of H3K27me3 with the Xist RNA coat 
can therefore be used as a readout of PRC2 activity (Figure 3).  
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Both X-inactivation and Polycomb group 
function have also been well-studied in mouse 
stem cell lines. Several types of stem cell lines 
can be derived from E3.5 mouse blastocyst-
stage embryos: these include extra-embryonic 
endoderm stem (XEN) cells, trophoblast stem 
(TS) cells, and mouse embryonic stem (ES) cells 
(Figure 2). XEN, TS, and ES cells derive from the 
portions of the blastocyst that go on to become 
the yolk sac, placenta, and the fetus, respectively. When stained via IF using antibodies 
against EZH2 and H3K27me3, combined with RNA FISH for Xist RNA, TS cells 
resemble blastocyst-stage embryos in that Xist, H3K27me3, and EZH2 are all enriched 
on the inactive-X (Plath et al., 2003). In XEN cells, however, while Xist and H3K27me3 
accumulate on the inactive-X, EZH2 is not enriched on the inactive-X (Figure 3).  
Figure 3: 
IF/FISH 
staining of 
Xist, 
H3K27me3, 
and EZH2 in 
representative 
wild-type 
female TS and 
XEN cells. 
Nuclei are 
stained with 
DAPI. Scale 
bars, 2.5 μm.  
Figure 2: Diagram of a mouse 
blastocyst (E3.5), from which XEN, 
TS, and ES cells can be derived. 
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Because of the lack of enrichment of EZH2 on the inactive-X as assessed by IF, 
we questioned whether another factor could also catalyze H3K27me3 on the inactive-X 
in XEN cells. We therefore decided to investigate the requirement for various core 
components of PRC2 for catalysis of H3K27me3. Our hypothesis is that a 
methyltransferase other than EZH2 can catalyze H3K27me3. 
This study is significant because in addition to providing insights into factors that 
contribute to the catalysis of the repressive histone modification H3K27me3, which is 
intrinsically of interest to chromatin biologists; the results can also be linked to more 
translational aspects, such as cancer therapy. Researchers have observed 
overexpression of EZH2, and consequently increased levels of H3K27me3, in various 
forms of cancer, including prostate and breast cancer (Varambally et al., 2002, Kleer et 
al., 2003). As such, inhibitors of EZH2 aimed at decreasing H3K27me3 levels, and 
hence potentially ameliorating the negative effects of high levels of H3K27me3, have 
been brought forward as cancer therapeutic agents (McCabe et al., 2012). If, however, 
there are EZH2-independent, or even PRC2-independent, pathways of H3K27me3 
catalysis, these therapies may not be fully effective in the treatment of cancer. 
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RESULTS AND DISCUSSION 
H3K27me3 catalysis in Ezh2-/- XEN cells  
In order to be able to 
examine the extent to which 
H3K27me3 is catalyzed in the 
absence of EZH2, a member of 
the lab generated Ezh2 mutant 
XEN cells for analysis (Clair 
Harris, Acknowledgements). 
To generate Ezh2-/- XEN cells, 
we first derived conditionally-
mutant Ezh2fl/fl XEN cells (Su et al., 2002). The XEN cell lines were generated from 
embryonic day (E) 3.5 mouse embryos in which exons 15-18, which encode the SET 
domain, are flanked by loxP sites (Ezh2fl/fl). Since the SET domain is the catalytic unit of 
EZH2, deletion of the SET domain ensures that regardless of whether a truncated 
protein is expressed, the mutation is null. Female Ezh2fl/fl XEN cells were then 
transfected with Cre recombinase to delete the floxed exons, generating a null allele 
(Ezh2-/-) (Figure 4). This strategy allows for direct comparison of parent cell lines in 
which Ezh2 is still present (Ezh2fl/fl) to the derivative cell line that is Ezh2 null (Ezh2-/-). 
Using genomic PCR, RT-PCR, and Western blotting, I validated that Ezh2 had 
been properly deleted in the Ezh2-/- XEN cells (Figure 5a-c). The Ezh2 deletion 
produces a truncated RNA (Figure 5b), but does not produce a stable truncated protein, 
Figure 4: Diagram of the conditional Ezh2 mutation used 
to delete Ezh2 in XEN cells. This figure is adapted from 
Figure 2 of Su et al., 2002. 
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as Western blotting using a 
monoclonal antibody against the 
residues of EZH2 surrounding Arg354 
(which corresponds to a region that is 
encoded for by a region of the gene 
that remains intact in the mutant 
allele) did not detect a shorter band 
(Figure 5d), and the lack of a 
truncated protein in this mutant allele 
has also been previously reported (Su 
et al., 2002).   
Having verified that Ezh2 had 
been homozygously deleted and that 
no protein is made following Cre 
transfection of the XEN cells, I 
performed H3K27me3 IF followed by 
Xist RNA FISH to assess whether 
H3K27me3 would accumulate on the inactive-X in the absence of EZH2 (Figure 6a). For 
this analysis, I used three different antibodies against H3K27me3 (Millipore, Active 
Motif, and Abcam). Quality control experiments by the manufacturers, as well as by 
other groups, suggests that these antibodies are highly specific and detect only 
H3K27me3 (Egelhofer et al., 2011). I counted three sets of 100 nuclei for each antibody 
in each cell line to quantify how often H3K27me3 was enriched on the inactive-X; the 
Figure 5: Ezh2 status in Cre-transfected Ezh2fl/fl 
female XEN cells. a. Ezh2 genomic PCR. b. 
Ezh2 RT-PCR. c-d. EZH2 Western blots on 30 
μg of whole cell lysates. 
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inactive-X is marked by Xist RNA accumulation (Figure 6b). For the two antibodies with 
better staining efficiency in Ezh2fl/fl  XEN cells (Millipore and Active Motif), the 
percentage of nuclei with accumulation of H3K27me3 on the inactive-X in Ezh2-/- XEN 
cells remained approximately the same as for Ezh2fl/fl XEN cells, although staining 
intensity throughout the nucleus was somewhat reduced (Figure 6b and data not 
shown). The third antibody (Abcam), however, which stained the inactive-X poorly even 
in Ezh2fl/fl XEN cells (at an efficiency of about 50% of Xist-coated nuclei), did not show 
accumulation of H3K27me3 on the inactive-X in Ezh2-/- XEN cells (Figure 6b).  
Because of this slight discrepancy between the different H3K27me3 antibodies, I 
decided to assess global levels of H3K27me3 in Ezh2-/- XEN cells. I extracted histones 
from Ezh2fl/fl and Ezh2-/- XEN cells and performed Western blotting against H3K27me3. 
For all three antibodies, H3K27me3 was detectable by Western blotting in the absence 
of EZH2, albeit at lower levels compared to the control cell line (Figure 6c). This 
confirms the results from the IF/ RNA FISH experiments. The findings further suggest 
that the lack of staining observed with the Abcam antibody is because of a decrease in 
the amount of H3K27me3; this antibody stains relatively weakly and is unable to detect 
the lower levels of H3K27me3 on the inactive-X by IF in the mutant cells. Nevertheless, 
from these data, it appears that despite the absence of EZH2 protein, H3K27me3 is 
able to be catalyzed and is still enriched on the inactive-X. 
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Figure 6: a. Immunofluorescence detection of H3K27me3 using three different antibodies in 
Ezh2fl/fl and Ezh2-/- female XEN cells. Xist RNA FISH marks the inactive-X. Scale bars, 2.5 μm. b. 
Quantification of Xist and H3K27me3 co-localization for Xist-coated nuclei. Mean ± standard 
error, n=300 (3 separate stains counted for 100 nuclei each). c. Histone extracts from Ezh2fl/fl and 
Ezh2-/- XEN cells analyzed by Western blotting for H3K27me3 using the three antibodies, as well 
as a histone H4 antibody and Coomassie staining of the histone extracts. 
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Figure 7: Diagram of the Ezh1 mutation used in this study. RT-PCR primers are shown as blue 
arrows, and genotyping primers are shown as green arrows (diagram created by Clair Harris) 
H3K27me3 catalysis in Ezh2-/-;Ezh1-/- XEN cells  
 Because of previous studies suggesting that EZH1, the homolog of EZH2, may 
have catalytic activity as part of PRC2 (Shen et al., 2008), we decided to investigate 
whether the residual H3K27me3 observed in Ezh2-/- XEN cells is attributable to EZH1 
taking the place of EZH2 in PRC2-mediated catalysis of H3K27me3. We therefore 
generated Ezh2fl/fl;Ezh1-/- XEN cells and transfected the derived cells with Cre to yield 
Ezh2-/-;Ezh1-/- XEN cells. Since the nature of this Ezh1 mutation has not been 
previously published (Acknowledgements), I characterized the genomic sequence of the 
construct by using a series of PCR primers and sequencing products. EZH1 has 21 
exons, of which exon 17 through half of exon 21 constitute the SET domain (Figure 7). 
The mutation consists of a 750 bp deletion in the middle of exon 7 extending into intron 
7-8, followed by an insertion containing a β-geo cassette and other vector sequences. 
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Using 
Ezh2fl/fl;Ezh1-/- mice to 
generate E3.5 embryos, 
we derived two 
Ezh2fl/fl;Ezh1-/- XEN cell 
lines, one male and one 
female. The lines were 
then transfected with Cre 
to induce conditional 
deletion of Ezh2. To 
verify the genotypes of 
the lines, I performed 
Ezh2 and Ezh1 genomic 
PCRs on the cell lines 
(Figure 8). I furthermore 
performed an Ezh1 RT-
PCR on the cell lines in order to assess whether there was any transcription from the 
mutant allele, as well as Ezh2 RT-PCRs for genotyping purposes (Figure 9a). The Ezh1 
mutation produces a truncated mRNA that is transcribed until the middle of Exon 7, 
where the deletion begins (Figure 9b). There are some instances where faint bands can 
be detected by using primers in scattered regions downstream of the deletion, but I did 
not find evidence of a continuous transcript that would produce a sizable protein, as 
assessed by RT-PCR primer pairs and 5’RACE (Figure 9c and data not shown).  
Figure 8: Genomic PCRs on XEN cell lines to detect wild-type 
and mutant alleles of a. Ezh2 and b. Ezh1. Mouse DNA was 
used in control lanes. 
16 
 
 
Figure 9: Verification of Ezh1 mutant XEN cells by RT-PCR analysis.  
a. Ezh1 RT-PCR using primers in exons 6 and 19, and Ezh2 RT-PCR to 
demonstrate genotypes of cells. b. RT-PCR using primers in exons 2 and 5 of Ezh1 
to show presence of the truncated mRNA transcript. c. Various primer sets showing 
lack of a continuous transcript in Ezh1 mutant XEN cells. Additional primer sets were 
also tested (data not shown). Figures 9A and 9C made by Clair Harris. 
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To check for protein 
products in the various mutant 
cell lines, I performed Western 
blotting for EZH2 (Figure 10). 
Unfortunately, the level of 
endogenous EZH1 protein 
appears to be too low in XEN 
cells to be detectable by Western 
blotting, based on my tests of six 
different antibodies against EZH1 
(Methods, Table 1). Because of 
this, I have not been able to 
unequivocally show that there is 
no EZH1 protein in the Ezh1-/- 
XEN cells. However, based on 
the RT-PCR data, it would be 
impossible for there to be a full-
length protein, and the SET 
domain is on the C-terminal end 
of the protein (which is after the 
deletion and insertion), making it 
unlikely that any potential 
methyltransferase activity of 
Figure 10: EZH2 Western blot using 30 μg of whole 
cell lysates from XEN cell lines. 
Figure 11: a. H3K27me3 Western blot using Millipore 
antibody, with histone H4 as a loading control and a 
Coomassie stain of histone preps. b. Quantification of 
band intensity, normalized to histone H4 loading 
control. Mean ± standard error, n=3. 
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EZH1 would remain functional in these cells, even if a shortened protein were made 
from the first seven exons. 
I then repeated the same set of analyses for H3K27me3 detection as in the  
Ezh2-/- single mutant XEN cells with our best antibody (Millipore). Surprisingly, 
H3K27me3 was still detectable by Western blotting even in Ezh2-/-;Ezh1-/- XEN cells 
(Figure 11a). The H3K27me3 and histone H4 Western blots were done using 
fluorescent secondary antibodies simultaneously in two different channels, and they 
were imaged in a SynGene G:Box gel-doc system. The use of this system, as well as its 
associated software, allows for accurate quantification of the fluorescent signal that 
does not rely on the use of scanning films. Using this quantification method, I 
determined that the amount of H3K27me3 in double mutant cells appeared to be the 
same as in Ezh2-/- single mutant XEN cells (Figure 11b).  
When I performed IF/ Xist RNA FISH on the Ezh2-/-;Ezh1-/- double mutant cells, 
however, there was no detectable enrichment of H3K27me3 with Xist on the inactive-X 
(Figure 12a-b). There was still background staining present for H3K27me3, however, 
and in some instances, nuclei took on a “speckled” appearance in which there were 
multiple foci of high DAPI staining intensity, and the H3K27me3 often co-localized with 
the DAPI foci in these instances, but not with the inactive-X (Figure 12c). These data 
suggest that in the absence of both EZH2 and EZH1, H3K27me3 is still catalyzed in 
XEN cells, but that specific enrichment of H3K27me3 on the inactive-X is impaired. This 
implies that targeting of H3K27me3 to the inactive-X requires either EZH2 and/or EZH1. 
This supports the idea that Xist RNA directly or indirectly recruits PRC2 in order to 
cause enrichment of H3K27me3 on the inactive-X chromosome. 
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Figure 12: a. Immunofluorescence detection of H3K27me3 using the Millipore antibody in Ezh2fl/fl, 
Ezh2-/-, Ezh2fl/fl;Ezh1-/-, and Ezh2-/-;Ezh1-/- female XEN cells. Xist RNA FISH marks the inactive-X. b. 
Quantification of H3K27me3 on Xist-coated nuclei. Mean ± standard error, n=300 for three separate 
counts of 100 nuclei each. c. Representative image of a subset of nuclei that display H3K27me3 
localization on spots of high DAPI staining intensity. Scale bars, 2.5 μm. 
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Figure 13: Diagram of the Eed mutation used in this study. RT-PCR primers are shown in blue; 
genotyping PCR primers are shown in green. 
H3K27me3 catalysis in Eed-/- XEN cells  
Since H3K27me3 was still present in Ezh2-/-;Ezh1-/- XEN cells, we wished to 
know if H3K27me3 is catalyzed in Eed-/- XEN cells. Previous work showed a complete 
absence of H3K27me3 in Eed-/- ES cells (Montgomery et al., 2005). We therefore 
hypothesized that another methyltransferase, instead of EZH2 or EZH1, might be 
associating with EED in order to catalyze H3K27me3. We therefore decided to generate 
Eed-/- XEN cells in order to test whether H3K27me3 would be abolished, which would be 
consistent with the hypothesis that the methyltransferase responsible for residual 
H3K27me3 in the Ezh2-/-;Ezh1-/- XEN cells does so via association with EED. Using 
mice with the mutation construct shown in Figure 13, a member of the lab (Clair Harris, 
see Acknowledgements) generated female Eedfl/- and Eed-/- XEN cells (one parental 
Eedfl/- line and two Eed-/-subclones after Cre transfection, #1 and #2) using a similar Cre 
transfection strategy as in the previous sections.  
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The Eed mutation used in 
this study results in a single exon 
deletion, exon 7, upon Cre 
transfection, as can be seen via 
PCR and RT-PCR (Figure 14a-b). 
Studies have shown that the 
WD40-repeat domains of EED are 
required for its interaction with 
EZH2 (Han et al., 2007). In fact, 
based on a series of truncation 
mutants, EED requires amino 
acids 90-441, which contain all of 
the 7 WD40 repeats, to interact 
with EZH2 (Sewalt et al., 1998). 
Expression of Eed constructs 
containing some, but not all, of the WD40 repeats results in a lack of interaction with 
EZH2 (Cao et al., 2014). Exon 7 (aa 212-242) encodes part of the 3rd and 4th WD40 
repeats (aa 193-229 and 239-264); therefore, deletion of this exon should prevent 
formation of PRC2 even if a partial EED protein were to form (the sequence of the 
mutant mRNA was also analyzed, and there is a predicted in-frame stop codon created 
by the deletion). 
 I then analyzed levels of H3K27me3 in histone extracts from Eedfl/- and Eed-/- 
XEN cells by fluorescent Western blotting and quantification, as described in the 
Figure 14: a. Genotyping PCR on Eed XEN cell lines. 
Mouse DNA is included as a control. b. RT-PCR using 
primers in Eed exons 5 and 12 to observe deletion of 
exon 7 in the mutant Eed XEN cell lines. (Experiments 
in this figure performed by Clair Harris). 
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previous section (Figure 15a-b). Unexpectedly, I found that H3K27me3 was still present 
at significant levels in both Eed-/- XEN cell subclones. 
 
Similarly, I analyzed H3K27me3 catalysis on the inactive-X in Eedfl/- and Eed-/- 
XEN cells using H3K27me3 IF and Xist RNA FISH (Figure 16a). Just as in Ezh2-/-; 
Ezh1-/- cells, loss of EED drastically reduced co-localization of H3K27me3 and Xist 
(Figure 16b). Based on this data, it appears that EED is necessary for accumulation of 
H3K27me3 on the inactive-X. This is in agreement with the data from the previous 
section, which showed that either EZH2 or EZH1 is necessary for localization of 
H3K27me3 to the inactive-X, but not for residual levels of global H3K27me3 catalysis. 
Taking these two sets of data together, the results are suggestive that PRC2 function is 
necessary for enrichment of H3K27me3 on the inactive-X, and that there is likely a 
PRC2-independent mechanism for catalysis of H3K27me3 in the absence of PRC2. 
Figure 15: a. H3K27me3 Western blot using Millipore antibody, as well as an antibody against 
histone H4 and a Denville Blue Protein stain of histone preps as loading controls. b. 
Quantification of band intensity for Eedfl/- and Eed-/- XEN lines, normalized to H4 loading control. 
Mean ± standard error, n=4. 
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Figure 16: a. Immunofluorescence detection of H3K27me3 using the 
Millipore antibody in Eedfl/- and Eed-/- female XEN cells. Xist RNA FISH marks 
the inactive-X. b. Quantification of H3K27me3 on Xist-coated nuclei. Mean ± 
standard error, n=300 for three separate counts of 100 nuclei each for Eed fl/- 
and Eed-/- #2; n=500 for five separate counts for Eed-/- #1. Scale bars, 2.5 μm. 
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DISCUSSION 
 In this study, I assessed catalysis of the repressive histone mark H3K27me3 in 
the absence of Polycomb group proteins EZH2, EZH1, and EED in XEN cells. The 
results of this study demonstrate that, as assessed by IF, H3K27me3 is still enriched on 
the inactive-X in the absence of EZH2, and as assessed by Western blotting, 
H3K27me3 catalysis still occurs in the absence of EZH2, EZH2 together with EZH1, and 
EED. These results therefore imply that there is an unknown PRC2-independent factor 
capable of catalyzing H3K27me3.  
Enrichment of H3K27me3 on the inactive-X is PRC2-dependent 
The levels of H3K27me3 were similar between Ezh2-/- and Ezh2-/-;Ezh1-/- XEN 
cells, which suggests that EZH1 does not contribute significantly to overall levels 
H3K27me3 catalysis in these cells. On the other hand, while single mutant Ezh2-/- and 
Ezh1-/- XEN cells showed no defects in levels or accumulation of H3K27me3 on the 
inactive-X, Ezh2-/-;Ezh1-/- XEN cells lacked enrichment of H3K27me3 on the inactive-X. 
These data imply that EZH2 and/or EZH1 is required for inactive-X-specific 
accumulation of H3K27me3. Eed-/- XEN cells also lacked accumulation of H3K27me3 
on the inactive-X, further cementing the idea that enrichment of H3K27me3 on the 
inactive-X is PRC2-dependent. These results are in agreement with the current model 
that Xist RNA may somehow target PRC2, and thereby H3K27me3, to the inactive-X. 
Further studies are necessary, however, to conclusively determine whether this is a 
direct interaction between Xist and PRC2 or an indirect effect caused by Xist 
expression, as recent studies disagree on which regions of Xist are necessary for PRC2 
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recruitment to the inactive-X, and reliable biochemical assays have yet to be performed 
(Da Rocha et al., 2014, Zhao et al., 2008).  
 The finding that H3K27me3 catalysis still occurred in Ezh2-/-;Ezh1-/- XEN cells 
helps to elucidate the discrepancy between two previous studies that describe 
conflicting results on the requirement of EZH1 for residual H3K27me3 in Ezh2-/- ES cells 
(Shen et al., 2008, Margueron et al., 2008). In one study, residual H3K27me3 in Ezh2-/- 
ES cells was abolished upon Ezh1 siRNA treatment (Shen et al., 2008), while the other 
study found that H3K27me3 was still present in Ezh2-/- ES cells treated with Ezh1 
siRNA (Margueron et al., 2008). In our study, H3K27me3 was clearly still catalyzed in 
Ezh2-/-;Ezh1-/- cells, supporting the results of the second study. Furthermore, our use of 
a germline null Ezh1 allele rather than siRNA allows for certainty of the depletion of 
EZH1 protein; in siRNA knockdown experiments, a complete knockdown of the protein 
of interest may not occur.  
Presence of H3K27me3 catalysis in Eed-/- XEN cells 
The finding that H3K27me3 was still catalyzed in Eed-/- XEN cells was highly 
unexpected, given previous data showing a lack of H3K27me3 in Eed-/- ES cells 
(Montgomery et al., 2005). There are several potential reasons as to the discrepancy 
between my results and previous data. Firstly, I believe that the fluorescent Westerns 
that I performed on purified histone extracts are more sensitive than the Western blots 
reported in previous studies. This idea is supported by the fact that even though others 
have reported H3K27me3 in the absence of EZH2 alone, the bands that I observe in my 
Ezh2-/- samples are much more robust compared to samples expressing EZH2 than in 
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analogous experiments in the literature (Shen et al., 2008, Margueron et al., 2008). 
Secondly, the previous studies resorted to examining ES cells; biochemical studies of 
ES cells are confounded by feeder cells that are required for proper growth and 
maintenance of the cell lines. In Westerns using ES cell lysates, faint bands can be 
attributed to feeder contamination, since it is difficult to ascertain that lysates are 
completely free of feeder cells. XEN cells do not require feeder cells for growth, allowing 
for the certainty that any H3K27me3 observed by Western blotting must be from the 
mutant XEN cells themselves. 
Before definitive conclusions can be made, however, it will be necessary to 
conclusively show that there is no functional EED protein in our putative Eed-/- XEN 
cells, since there is a shortened, but not truncated, RNA produced in this cell line. 
Preliminarily, this shortened RNA is also less abundant than the wild-type Eed RNA. If, 
however, a shortened EED protein is produced from the mutant allele, I cannot exclude 
the possibility that this protein could be participating in the formation of the PRC2 
complex, thus facilitating PRC2-dependent catalysis of H3K27me3. Arguing against this 
possibility, however, is the fact that our Eed mutation removes part of two WD40 
repeats, and these WD40 domains have been shown to be required for EZH2 binding 
and EED function in the catalysis of H3K27me3 as part of PRC2 (Cao et al., 2014, 
Sewalt et al., 1998). If I do find evidence of a truncated protein in the Eed-/- XEN cells, I 
will need to perform immunoprecipitation to determine whether the PRC2 complex still 
forms. In this case, the H3K27me3-catalyzing methyltransferase could still be part of 
PRC2 and associate with the mutant EED protein. An EED immunoprecipitation could 
then be used to purify and identify the unknown methyltransferase. 
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A potential novel PRC2-independent histone methyltransferase capable of 
H3K27me3 catalysis 
 If I determine that there is no shortened EED protein in the Eed-/- XEN cells that 
is responsible for residual H3K27me3, then the presence of H3K27me3 in these cells 
implies the existence of a novel histone methyltransferase that catalyzes H3K27me3 in 
the absence of functional PRC2 components. The next step, then, would be to discover 
the identity of this methyltransferase. This process is complicated by the fact that in this 
case, the methyltransferase does not associate with EED, so there is no means of 
purifying it through interaction with EED. An alternative option is to examine known 
SET-domain containing proteins and use siRNA knockdown in both Ezh2-/- and Ezh2-/-; 
Ezh1-/- XEN cells to look for whether knockdown of any of the proteins causes depletion 
of the residual H3K27me3 in these cell lines. To date, with only one exception, all lysine 
methyltransferases contain a SET domain, facilitating this approach (Dillon et al., 2005). 
Another potential method to identify the H3K27me3-catalyzing enzyme is an intensive 
column chromatography-based protein purification, using H3K27me3 activity as the 
readout of the purified proteins. 
 Whether or not the identity of the methyltransferase is discovered, this study is 
still significant in that it demonstrates the existence of H3K27me3 catalysis activity that 
is independent of EZH2, EZH1, and potentially EED. As such, it should not be expected 
that inhibition of EZH2 or EED in cancers that have a hyperabundance of the 
H3K27me3 mark will result in complete inhibition of H3K27me3 catalysis. 
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METHODS 
Cell Lines 
XEN cells were derived as described previously (Kalantry et al., 2006). Briefly, 
E3.5 embryos were flushed from the mouse uterus with medium (MEMα/10% fetal 
bovine serum) and plated individually on MEFs (mouse embryonic feeder cells) into 
wells of a 4-well tissue culture dish containing 750 μl of XEN derivation medium (MEMα, 
50 μg/ml penicillin/streptomycin (Invitrogen, #15070063), 20% fetal bovine serum, 1 mM 
sodium pyruvate, 100 μM β-mercaptoethanol, 2mM L-glutamine, 100μM non-essential 
amino acids (Gibco, #11140-050), 1000 units/ml Leukemia Inhibitory Factor (LIF, 
Millipore #ESG1107)). After 6-8 days of growth at 37˚C with 5% CO2, blastocyst 
outgrowths were dissociated using 0.05% trypsin. Cells were then plated on MEFs into 
individual wells of a 96-well dish containing XEN derivation medium and cultured at 
37˚C with 5% CO2.Cells were screened by morphology and then passaged into 4-well 
wells following confluency, and then finally into 6-well wells without MEFs. For 
maintenance of derived cell lines, XEN cells were grown in XEN medium (MEMα, 20% 
fetal bovine serum, 1 mM sodium pyruvate, 100 μM β-mercaptoethanol, 2 mM L-
glutamine, 100 μM non-essential amino acids) on gelatinized wells without feeders. 
XEN cell lines were characterized both by morphology and by expression of XEN-
specific factors, assessed by RT-PCR (data not shown).  
TS cells derivation, culture, and characterization was carried out as described 
previously (Kalantry et al., 2006). 
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RNA Fluorescence in situ Hybridization (RNA FISH) probe 
Double stranded Xist probes were generated using random priming of the Xist 
gene using BioPrime DNA Labeling System (Invitrogen, #18094011). Labeling was 
performed at 37˚C overnight using Fluorescein-12-dUTP (Invitrogen), Cy3-dCTP (GE 
Healthcare, #PA53021), or Cy5-dCTP (GE Healthcare, #PA55031). Following labeling, 
probes were purified using a G50 Sephadex column, precipitated in a 0.3M sodium 
acetate solution with 200 μg yeast tRNA and 100% ethanol. Probes were spun down at 
16,000x g for 20 minutes at 4˚C, then re-dissolved in 100% ethanol, with 0.01M sodium 
acetate. One tenth of this labeled probe stock solution was then precipitated in a 3M 
sodium acetate solution with 300 μg yeast tRNA (Invitrogen, #15401-029), 15 μg of 
mouse COT-1 DNA (Invitrogen, #18440-016), and 150 μg of sheared, boiled salmon 
sperm DNA (Invitrogen, #15632-011), then spun at 16,000 x g at 4˚C for 20 minutes. 
The pelleted probe was then washed with 70% ethanol, spun down, washed with 100% 
ethanol, and dried. The washed probe was then re-suspended in deionized formamide 
and denatured for 10 minutes at 90˚C, followed by an immediate incubation on ice for 5 
minutes. A 2X hybridization solution (4X SSC, 20% dextran sulfate (Millipore, #S5030), 
2.5 mg/ml purified BSA (New England BioLabs, #B90018)) was added to the denatured 
probe, resulting in a 1X hybridization /50% formamide solution. Probes were stored at -
20˚C prior to use in IF/FISH experiments. 
Immunofluorescence (IF) and IF/FISH 
Cells were split onto gelatinized glass coverslips and grown to confluency (2-3 
days). To permeablize, cells were incubated for 20-30 seconds in cytoskeletal buffer 
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(CSK: 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM PIPES pH 6.8), then for 
20-30 seconds in CSK containing 0.4% Triton X-100, then again for 20-30 seconds in 
CSK. (Eed-/- XEN cells were treated for twice as long in the aforementioned conditions). 
Cells were fixed for 10 minutes in 4% paraformaldehyde, washed twice with 70% 
ethanol, and then stored at -20˚C in 70% ethanol. 
Processed cells were rinsed three times in 1X PBS, then washed three times for 
3 min each while shaking. The samples were then incubated in blocking buffer (0.5 
mg/ml BSA (New England BioLabs, #B9001S), 50 μg/ml yeast tRNA (Invitrogen, 
#15401-029), 80 units/ml RNAseOUT (Invitrogen, #10777-019), and 0.2% Tween-20, in 
1X PBS) in a humid chamber at 37˚C for 30 minutes. Following the blocking step, cells 
were incubated with primary antibody, diluted in blocking buffer, in a humid chamber at 
37˚C for 1 hour. Next, cells were washed three times for 3 minutes each in 1X PBS, 
0.2% Tween-20 while shaking. The samples were incubated again in blocking buffer for 
5 minutes in the humid chamber at 37˚C, then incubated in a 1:300 dilution of 
fluorescently-conjugated secondary antibody (Alexa Fluor, Invitrogen), diluted in 
blocking buffer, for 30 minutes in the humid chamber at 37˚C. Samples were washed 
three times in PBS/0.2% Tween-20 as above, and then either processed for RNA FISH 
or mounted on microscope slides using Vectashield with DAPI (Vector Labs,#H-1200) 
and sealed with clear nail polish.  
For IF/FISH, cells were washed for 5 minutes in 70% ethanol at room 
temperature, dehydrated through a series of 5 minute incubations in 85%, 95%, and 
100% ethanol solutions, and then air-dried. Coverslips were then incubated with a 
double-stranded Xist probe and hybridized overnight at 37˚C in a humid chamber. 
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Following hybridization, samples were washed for 7 minutes each in a humid chamber 
at 39˚C 3 times with 2X SSC/50% formamide, 3 times with 2X SSC, and twice with 1X 
SSC, with a 1:200,000 dilution of DAPI (Invitrogen, #D21490) added to the third 2X SSC 
wash. Coverslips were mounted on glass slides with Vectashield (Vector Labs, #H-
1000) and sealed with clear nail polish. 
Microscopy 
 Stained cells were visualized and imaged using a Nikon Eclipse TiE inverted 
microscope with a Photometrics CCD camera. Images were deconvolved and uniformly 
processed using NIS-Elements software. Published images are maximum intensity 
projections of Z-stacks spanning multiple planes of focus. 
Protein Lysate Collection 
For whole cell extracts, cells (grown for a few days in gelatinized tissue culture 
plates without feeders for ES and TS cells) were washed in cold 1X PBS, then 
incubated in modified RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium 
deoxycholate, 150 mM NaCl) with protease inhibitors (Complete Protease Inhibitor 
tablet (catalog number), 1 mM PMSF, and a 1:100 dilution of Aprotinin (EMD 
Millipore/Calbiochem, #616399-100KU)) for 10 minutes on ice with mild agitation. 
Lysates were then collected using a cell scraper and sonicated three times for 30 
seconds each, with 1 minute rest periods in between. Lysates were then spun for 15 
minutes at 16,000 x g at 4˚C to remove insoluble components. 
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Acid Extraction of Histones. 
Isolation of histones was performed essentially as described in Shechter et al., 
2007. Briefly, cells were pelleted, washed with 1X PBS, resuspended in hypotonic lysis 
buffer (10 mM Tris pH 8.0, 1 mM KCl, 1.5 mM MgCl2) with protease inhibitors (1 mM 
DTT, 1 mM PMSF, Complete Mini EDTA Protease Inhibitor Tablets, catalog number), 
rocked at 4˚C for 30 minutes, and then spun down at 10,000g for 10 min at 4˚C to pellet 
nuclei. Nuclei were then resuspended in 0.2M H2SO4 and incubated overnight at 4˚C. 
Histones, which were present in the supernatant, were precipitated by adding 
trichloroacetic acid and incubating for 30 minutes on ice. Histones were pelleted at 
16,000g for 10 min at 4˚C, subjected to a series of acetone washes, and then dissolved 
in ddH2O. To assess purity, 5 μg of histone samples were run on 15% polyacrylamide 
gels, then stained with Denville Blue Protein Stain (Denville Scientific, #E2700-SA). 
Western Blotting and Quantification 
 For EZH2 Western blots, 30 μg of whole cell extracts were loaded in gels. For 
H3K27me3 Western blots, 15 μg of acid extracted histones were loaded in gels. 
Western blotting was performed using the antibodies listed below with the dilutions in 
Table 1. EZH2 Western blots were performed using HRP-labeled secondary antibodies 
at a dilution of 1:5000 and detected using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, #34079) in a G:Box iChemiXR (Syngene) with GeneSys 
software (v.1.2.5.0) using no light and no filter H3K27me3 and H4 Western blots were 
performed using fluorescently-conjugated secondary antibodies (Alexa Fluor, 
Invitrogen) at a dilution of 1:300 and detected/imaged using G:Box iChemiXR with the 
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FRLP filter and Lights Red LED (RGB) for the 647 wavelength and the SGNB filter and 
Lights Green LED (RGB) for the 555 wavelength. Quantification of band intensity was 
performed on unsaturated fluorescent images using Syngene Genetools software, and 
values were normalized to the intensity of the H4 loading control for each lane.  
Antibodies 
Table 1: The antibodies used in Western blotting and IF experiments (with dilutions) 
Antibody Supplier Raised in Western 
Blot 
IF 
 
EZH2 Cell Signaling (DC29) Rabbit (mAb) 1:1000 1:200 
H3K27me3 Millipore (ABE44) Rabbit (pAb) 1:5000 1:5000 
H3K27me3 Active Motif (39155) Rabbit (pAb) 1:5000 1:1000 
H3K27me3 Abcam (ab6002) Mouse (mAb) 1:500 1:200 
H3K27me3* Millipore (07-449) Rabbit (pAb) 1:2500 Still determining 
EZH1 Millipore (ABE281) Rabbit (pAb) 1:2500 N/A 
EZH1 Abcam (ab137693) Rabbit (pAb) 1:500 N/A 
EZH1 Abcam (ab64850) Rabbit (pAb) 1:250 N/A 
EZH1 LS Bio (LS-C676) Rabbit (pAb) 1:250 N/A 
EZH1 LS Bio (LS-C176828) Rabbit (pAb) 1:750 N/A 
EZH1 Company (LS-C144356) Rabbit (pAb) 1:500 N/A 
EED Millipore      (09-774) Rabbit (pAb) 1:1000 N/A 
β-actin Sigma Aldrich (A5060) Rabbit (pAb) 1:5000 N/A 
Histone H4 Cell Signaling (L64C1) Mouse (mAb) 1:500 N/A 
 
*Note: All experiments are in the process of being repeated with this antibody (Millipore, 
07-449). So far, by Western blotting, the antibody shows the same results as the 
antibody described in this study (Millipore, ABE44) for all XEN cell genotypes described 
in the study, including Ezh2-/-, Ezh2-/-;Ezh1-/- and Eed-/-. IF experiments with this 
antibody are still undergoing optimization. 
 
RT-PCR and PCR Primers 
For RT-PCR experiments, total RNA was isolated from cells using Trizol reagent 
(Life Technologies, #15596018) in order to do a phenol-chloroform extraction. mRNA 
was purified from total RNA using the Dynabeads mRNA DIRECT Micro Kit (Life 
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Technologies, #61012). RT-PCR was performed using Superscript III One-Step RT-
PCR System with Platinum Taq DNA Polymerase (Life Technologies, #12574-026). 
Table 2: List of Primers, sequences, and their uses. 
 
 
 
 
 
 
 
 
 
Primer (F/R) Sequence Use Figure 
Ezh2-5-loxP-3 (F) CTGGCTCTGTGGAACCAAAC Ezh2 PCR 5A, 8A 
Ezh2-L5-loxP-1 (F) ATGGGCCTCATAGTGACAGG Ezh2 PCR 5A, 8A 
Enx1-3-loxP (R) GGAGTTGCCATTCAGAGCAG Ezh2 PCR 5A, 8A 
Ezh2delete 5-2 (F) AACACCAAACAGTGTCCATGCTAC Ezh2 RT-PCR 5B, 9A 
Ezh2delete 3-2(R) CTAAGGCAGCTGTTTCAGAGAGAA Ezh2 RT-PCR 5B, 9A 
Ezh1SA-1 (F) GTACTCTTAACCACTGGACTG Ezh1 PCR 8B 
Ezh1WT-3 (R) GTCTTGCTATGAGGACAGGAG Ezh1 PCR 8B 
Ezh1LACZ-2(R) CCTGAATGGCGAATGGCGCTT Ezh1 PCR 8B 
Ezh1ex2F (F) CGTCTGCAGAACAGAGGTA Ezh1 RT-PCR 9C 
Ezh1ex3F (F) GAGTATATGCGGCTTCGACA Ezh1 RT-PCR 9C 
Ezh1ex4F (F) AAATTTTGCAAAGGTTCAAG Ezh1 RT-PCR 9C 
Ezh1ex5F (F) TTGATGCGGTCTCTGAACAC Ezh1 RT-PCR 9C 
Ezh1ex6F (F) TACATGGGTGACGAGGTGAA Ezh1 RT-PCR 9A 
Ezh1WalkEx8F (F) GCAACAAAAAGAGTTCCAAG Ezh1 RT-PCR 9C 
Ezh1Setex19R (R) CATAACAGTTGGGGTTCACT Ezh1 RT-PCR 9A & C 
Ezh1ex5R1 (R) ATCAACATATCCTGGCTGTC Ezh1 RT-PCR 9B 
EED 5’ (F) GGACTCATCCTCTGGTAGAGCAGC Eed PCR 14A 
EED 3’a (R) TCAGCCTCAAGGGACTATCG Eed PCR 14A 
EED R1 (R) TCAATTGGTGGGTTTTGGAT Eed PCR 14A 
EEDexon5F (F) AACACCAGCCACCCTCTATT Eed RT-PCR 14B 
EEDexon12R (R) ATGATGGGTCAGTGTTGTGC Eed RT-PCR 14B 
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